These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 30652518)

  • 41. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel Agents for Acute Myeloid Leukemia.
    Luppi M; Fabbiano F; Visani G; Martinelli G; Venditti A
    Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30423907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
    Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
    Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of targeted therapy in the management of patients with AML.
    Perl AE
    Blood Adv; 2017 Nov; 1(24):2281-2294. PubMed ID: 29296877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. AML: New Drugs but New Challenges.
    Burnett A; Stone R
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
    Krauss AC; Gao X; Li L; Manning ML; Patel P; Fu W; Janoria KG; Gieser G; Bateman DA; Przepiorka D; Shen YL; Shord SS; Sheth CM; Banerjee A; Liu J; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
    Clin Cancer Res; 2019 May; 25(9):2685-2690. PubMed ID: 30541745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluating ivosidenib for the treatment of acute myeloid leukemia.
    Donker ML; Ossenkoppele GJ
    Expert Opin Pharmacother; 2020 Dec; 21(18):2205-2213. PubMed ID: 32808831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
    Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
    Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
    [TBL] [Abstract][Full Text] [Related]  

  • 49. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
    Yilmaz M; Daver N
    Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What are the most promising new agents in acute myeloid leukemia?
    Sallman DA; Lancet JE
    Curr Opin Hematol; 2017 Mar; 24(2):99-107. PubMed ID: 28030373
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
    Estey E; Karp JE; Emadi A; Othus M; Gale RP
    Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New therapeutic agents for acute myeloid leukemia].
    Hosono N
    Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.
    Andreozzi F; Massaro F; Wittnebel S; Spilleboudt C; Lewalle P; Salaroli A
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
    Maakaron JE; Mims AS
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
    Janus SE; Heisler AC; Al Jammal M; Chahine N; Chami T; Hajjari J; Mously H; Badhwar A; Arora S; Al-Juhaishi T; Al-Kindi SG; Hoit BD
    Curr Probl Cardiol; 2022 Nov; 47(11):101345. PubMed ID: 35948197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Acute myeloid leukemia].
    Döhner K; Paschka P; Döhner H
    Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparative safety review of targeted therapies for acute myeloid leukemia.
    Dalgetty M; Leurinda C; Cortes J
    Expert Opin Drug Saf; 2023; 22(12):1225-1236. PubMed ID: 38014918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.